Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus CIALIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus CIALIS.
ADCIRCA vs CIALIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.
10 mg orally three times daily.
Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
The terminal elimination half-life of tadalafil is approximately 17.5 hours in healthy subjects, which supports once-daily dosing for erectile dysfunction and once-daily use for benign prostatic hyperplasia. This long half-life distinguishes it from other PDE5 inhibitors.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Following oral administration, tadalafil is predominantly eliminated by hepatic metabolism. The metabolites are excreted mainly in feces (approximately 61% of the dose) and to a lesser extent in urine (approximately 36% of the dose). No unchanged parent drug is detected in urine.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor